(Q30853941)

11 November 2017

1 reference

Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis (English)

1 reference

11 November 2017

1 reference

Shelley S Selph

1

1 reference

11 November 2017

Alexander D Ginsburg

series ordinal

2

1 reference

11 November 2017

Roger Chou

series ordinal

3

1 reference

11 November 2017

19 September 2014

1 reference

11 November 2017

1 reference

11 November 2017

3

1 reference

11 November 2017

107

1 reference

https://scigraph.springernature.com/pub.10.1186/2046-4053-3-107

11 November 2017

0 references

cites work

Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Role of hyaluronic acid, its degrading enzymes, degradation products, and ferritin in the assessment of fibrosis stage in Egyptian patients with chronic hepatitis C.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Can aspartate aminotransferase to platelet ratio index replace liver biopsy in chronic hepatitis C?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Routine blood tests to predict liver fibrosis in chronic hepatitis C.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

A new scoring system for prediction of fibrosis in chronic hepatitis C.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI)

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

A new index for non-invasive assessment of liver fibrosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Systematic reviewers commonly contact study authors but do so with limited rigor

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Author contacts for retrieval of data for a meta-analysis on exercise and diet restriction

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Progression of liver fibrosis among injection drug users with chronic hepatitis C.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Retrieval of missing data for meta-analysis: a practical example

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients.

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Comparing the aspartate aminotransferase (AST) to platelet ratio index (APRI) between African American and White veterans with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Optimization and robustness of blood tests for liver fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

A novel panel of blood markers to assess the degree of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

King's Score: an accurate marker of cirrhosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Association of genetic polymorphism -670A>G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Serum markers detect the presence of liver fibrosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Noninvasive assessment of liver steatosis, fibrosis and inflammation in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2046-4053-3-107

Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4185334

Prediction of significant fibrosis in chronic hepatitis C patients with normal ALT

25 November 2018

1 reference

12 December 2020

Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases

1 reference

12 December 2020

Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests

1 reference

12 December 2020

A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C

1 reference

12 December 2020

Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C

1 reference

12 December 2020

Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis

1 reference

12 December 2020

APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C

1 reference

12 December 2020

External validation of FibroIndex

1 reference

12 December 2020

The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C

1 reference

12 December 2020

Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index

1 reference

12 December 2020

Identifiers

DOI

10.1186/2046-4053-3-107

1 reference

Dimensions Publication ID

11 November 2017

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/2046-4053-3-107

1 reference

11 November 2017

1 reference